06.30.17
New Brunswick, NJ
www.jnj.com
Sales: $7.4 billion for oral and personal care products.
Corporate sales: $71.9 billion.
Key Personnel: Alex Gorsky, chairman and chief executive officer; Dominic J. Caruso, executive vice president, chief financial officer; Jorge Mesquita, executive vice president, worldwide chairman, consumer; Paul Stoffels, MD, executive vice president, chief scientific officer.
Major Products: Johnson’s, Penaten and Desitin baby care products; Aveeno, Clean & Clear, Johnson’s, Neutrogena, Le Petit Marseillais beauty products.
New Products: Neostrata ProSystem Retinol Peel, Exuviance Body Tone Firming Concentrate, Exuviance Retexturing Treatment, Neutrogena HydroBoost line expansion.
Comments: Johnson & Johnson’s primary businesses, medical devices and pharmaceuticals, account for about two-thirds of the company’s nearly $72 billion in annual sales. But the company continues to make investments in consumer brands, witness last year’s acquisitions of Vogue International and Neostrata, which are already paying dividends.
Beauty care sales jumped 7.3%, due in part to a 4.6% contribution from Vogue International. Gains from Neostrata, Neutrogena, Aveeno and Dabao boosted beauty care sales, too, to help offset a negative currency impact of 2.1%.
Baby care sales fell 7.2% to $2.0 billion. J&J blamed the decline on heated competition, partially offset by sales of Aveeno baby products.
Oral care sales dipped 0.8%, as a 2.0% gain in sales was more than offset by a negative currency impact of 0.8%. Listerine provided a lift to sales, thanks to the introduction of new products and successful marketing campaigns.
In January, J&J Innovation LLC (JJIL), invested in S-Biomedic, which is focused on the microbiome-based solutions for skin care. S-Biomedic has developed a method to directly modulate the skin microbiome with applications in dermatology and the cosmetic industry. Last year, JJIL launched JLINX to identify and nurture early stage companies with the potential to transform human health. Launched in partnership with Bioqube Ventures and located on the Janssen R&D Campus in Beerse Belgium, JLINX offers startups a spectrum of flexible resources and approaches to grow and collaborate across the European life science ecosystem.
In March, J&J struck a blow for science when a jury rejected a lawsuit in which the plaintiff claimed Johnson & Johnson baby power contributed to her ovarian cancer. The announcement marked a victory for J&J following three similar lawsuits in St. Louis in which juries awarded a total of $197 million to plaintiffs who had made similar claims.
For the first quarter of 2017, consumer product sales increased 1% to $3.2 billion, but that total includes OTC products that are beyond Happi’s scope.
www.jnj.com
Sales: $7.4 billion for oral and personal care products.
Corporate sales: $71.9 billion.
Key Personnel: Alex Gorsky, chairman and chief executive officer; Dominic J. Caruso, executive vice president, chief financial officer; Jorge Mesquita, executive vice president, worldwide chairman, consumer; Paul Stoffels, MD, executive vice president, chief scientific officer.
Major Products: Johnson’s, Penaten and Desitin baby care products; Aveeno, Clean & Clear, Johnson’s, Neutrogena, Le Petit Marseillais beauty products.
New Products: Neostrata ProSystem Retinol Peel, Exuviance Body Tone Firming Concentrate, Exuviance Retexturing Treatment, Neutrogena HydroBoost line expansion.
Comments: Johnson & Johnson’s primary businesses, medical devices and pharmaceuticals, account for about two-thirds of the company’s nearly $72 billion in annual sales. But the company continues to make investments in consumer brands, witness last year’s acquisitions of Vogue International and Neostrata, which are already paying dividends.
Beauty care sales jumped 7.3%, due in part to a 4.6% contribution from Vogue International. Gains from Neostrata, Neutrogena, Aveeno and Dabao boosted beauty care sales, too, to help offset a negative currency impact of 2.1%.
Baby care sales fell 7.2% to $2.0 billion. J&J blamed the decline on heated competition, partially offset by sales of Aveeno baby products.
Oral care sales dipped 0.8%, as a 2.0% gain in sales was more than offset by a negative currency impact of 0.8%. Listerine provided a lift to sales, thanks to the introduction of new products and successful marketing campaigns.
In January, J&J Innovation LLC (JJIL), invested in S-Biomedic, which is focused on the microbiome-based solutions for skin care. S-Biomedic has developed a method to directly modulate the skin microbiome with applications in dermatology and the cosmetic industry. Last year, JJIL launched JLINX to identify and nurture early stage companies with the potential to transform human health. Launched in partnership with Bioqube Ventures and located on the Janssen R&D Campus in Beerse Belgium, JLINX offers startups a spectrum of flexible resources and approaches to grow and collaborate across the European life science ecosystem.
In March, J&J struck a blow for science when a jury rejected a lawsuit in which the plaintiff claimed Johnson & Johnson baby power contributed to her ovarian cancer. The announcement marked a victory for J&J following three similar lawsuits in St. Louis in which juries awarded a total of $197 million to plaintiffs who had made similar claims.
For the first quarter of 2017, consumer product sales increased 1% to $3.2 billion, but that total includes OTC products that are beyond Happi’s scope.
